Ambry Hits Myriad With Antitrust Claim In Gene Test IP Row

Law360, New York (August 6, 2013, 4:06 PM EDT) -- Ambry Genetics Corp. claimed Monday that Myriad Genetics Inc. has violated antitrust law and is trying to monopolize the market for breast cancer gene tests by filing a patent suit over Ambry's competing test.

Ambry filed counterclaims alleging violations of the Sherman Act and claiming that the patents at issue in Myriad's July suit against Ambry, which cover DNA primers and methods of screening for breast cancer genes, are invalid under recent U.S. Supreme Court decisions.

According to Ambry, Myriad knows the patents are invalid and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.